Bigger pharma may be scraping for good deals, but Horizon has plenty of options, analysts say

Carly Helfand

isn't exactly the only specialty company hunting for . Allergan, Mallinckrodt, Endo and the ever-acquisitive Valeant have all been on shopping sprees lately, leaving some wondering just what's left worth buying in the space.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS